AOPEP variants as a novel cause of recessive dystonia: Generalized dystonia and dystonia-parkinsonism.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
04 2022
Historique:
received: 09 02 2022
revised: 03 03 2022
accepted: 09 03 2022
pubmed: 21 3 2022
medline: 20 5 2022
entrez: 20 3 2022
Statut: ppublish

Résumé

The genetic basis of autosomal-recessive dystonia remains poorly understood. Our objective was to report identification of additional individuals with variants in AOPEP, a recently described gene for recessively inherited dystonic disorders (OMIM:619565). Ongoing analysis on a high-throughput genetic platform and international case-recruitment efforts were undertaken. Novel biallelic, likely pathogenic loss-of-function alleles were identified in two pedigrees of different ethnic background. Two members of a consanguineous Iranian family shared a homozygous c.1917-1G>A essential splice-site variant and featured presentations of adolescence-onset generalized dystonia. An individual of Chinese descent, homozygous for the nonsense variant c.1909G>T (p.Glu637*), displayed childhood-onset generalized dystonia combined with later-manifesting parkinsonism. One additional Iranian patient with adolescence-onset generalized dystonia carried an ultrarare, likely protein-damaging homozygous missense variant (c.1201C>T [p.Arg401Trp]). These findings support the implication of AOPEP in recessive forms of generalized dystonia and dystonia-parkinsonism. Biallelic AOPEP variants represent a worldwide cause of dystonic movement-disorder phenotypes and should be considered in dystonia molecular testing approaches.

Identifiants

pubmed: 35306330
pii: S1353-8020(22)00065-7
doi: 10.1016/j.parkreldis.2022.03.007
pii:
doi:

Substances chimiques

AOPEP protein, human EC 3.4.11.-
Aminopeptidases EC 3.4.11.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-56

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Barbara Garavaglia (B)

Department of Diagnostic and Technology, Medical Genetics and Neurogenetics Unit, Fondazione IRCCS Istituto Neurologico "C.Besta", Milan, Italy.

Sadeq Vallian (S)

Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Islamic Republic of Iran.

Luigi M Romito (LM)

Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico "C.Besta", Milan, Italy.

Giulia Straccia (G)

Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico "C.Besta", Milan, Italy.

Marianna Capecci (M)

Department of Experimental and Clinical Medicine, Neurorehabilitation Clinic, University Hospital "Ospedali Riuniti di Ancona", "Politecnica delle Marche" University, Ancona, Italy.

Federica Invernizzi (F)

Department of Diagnostic and Technology, Medical Genetics and Neurogenetics Unit, Fondazione IRCCS Istituto Neurologico "C.Besta", Milan, Italy.

Elisa Andrenelli (E)

Department of Experimental and Clinical Medicine, Neurorehabilitation Clinic, University Hospital "Ospedali Riuniti di Ancona", "Politecnica delle Marche" University, Ancona, Italy.

Arezu Kazemi (A)

Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Islamic Republic of Iran.

Sylvia Boesch (S)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Robert Kopajtich (R)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; Technical University of Munich, School of Medicine, Institute of Human Genetics, Munich, Germany.

Nahid Olfati (N)

Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohammad Shariati (M)

Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Qaem Medical Center, Mashhad, Iran; Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi, Mashhad, Iran.

Ali Shoeibi (A)

Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Qaem Medical Center, Mashhad, Iran.

Ariane Sadr-Nabavi (A)

Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Qaem Medical Center, Mashhad, Iran; Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi, Mashhad, Iran; Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Holger Prokisch (H)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; Technical University of Munich, School of Medicine, Institute of Human Genetics, Munich, Germany.

Juliane Winkelmann (J)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; Technical University of Munich, School of Medicine, Institute of Human Genetics, Munich, Germany; Lehrstuhl für Neurogenetik, Technische Universität München, Munich, Germany; Munich Cluster for Systems Neurology, SyNergy, Munich, Germany.

Michael Zech (M)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; Technical University of Munich, School of Medicine, Institute of Human Genetics, Munich, Germany. Electronic address: michael.zech@mri.tum.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH